Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
250
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Sjogren's Disease
Interventions
BIOLOGICAL:
Telitacicept
DRUG:
Placebo
Sponsor
Vor Biopharma